Retail cannabis accessibility directly impacts patient medication continuity and dosing consistency. Geographic barriers to legal dispensaries can force patients into unregulated markets, compromising therapeutic outcomes and safety monitoring.
Rhode Island’s recreational cannabis retail rollout faces local municipal resistance, creating a patchwork of access that mirrors early medical cannabis implementation patterns. This regulatory fragmentation typically results in concentrated retail locations in permissive municipalities while creating access deserts in restrictive areas. The clinical implications parallel those seen during medical cannabis expansion – inconsistent product availability, variable quality oversight, and potential gaps in patient access to established therapeutic regimens.
“We’ve seen this movie before with medical cannabis – municipal opt-outs create real therapeutic discontinuity for patients who rely on specific products or formulations. The politics of zoning shouldn’t determine whether someone can maintain their established cannabis medicine routine.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
